Organon & Co. (NYSE: OGN) is a Healthcare company (Drug Manufacturers - General) with a market capitalization of $3.7B. The Maz Rating grades it against the other companies in its sector.
Organon & Co.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $13.90, Organon & Co. trades at 17.6x trailing earnings, 0.6x sales and 3.1x book value, with an EV/EBITDA of 8.3. Over the last twelve months it generated about $6.1B of revenue and $207M of net income. It runs a gross margin of 53.4%, an operating margin of 19.5% and a net margin of 3.5%. It shows return on equity of 22.1%, return on invested capital of 4.7% and a free cash flow yield of 18.5%. On the balance sheet: a debt-to-equity ratio of 7.17 and a current ratio of 2.02. Over the past 52 weeks the share price ranged from $5.69 to $13.91, with a beta of 1.52.
Organon & Co. pays a dividend yielding 0.58%, with 9% of earnings paid out. Its Maz Dividend Score is 2.50 out of 5, ranked against the other dividend payers in its sector (Safety 3.97, Growth 1.77, Yield 3.43, Consistency 1.10).
9 Wall Street analyst ratings cover the stock: 2 Buy, 4 Hold and 3 Sell, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.